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C-Glucopyranosyl-1,2,4-
triazoles are novel skeletons to 
inhibit glycogen phosphorylase 
in the nanomolar range. 
Best inhibitors of rabbit muscle  R = 4-aminophenyl Ki   0.67 µM 
glycogen phosphorylase b R = 2-naphthyl Ki   0.41 µM 
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Abstract 
O-Perbenzoylated 5-(β-D-glucopyranosyl)tetrazole was reacted with N-benzyl carboximidoyl 
chlorides to give the corresponding 4-benzyl-3-(β-D-glucopyranosyl)-5-substituted-1,2,4-
triazoles. Removal of the O-benzoyl and N-benzyl protecting groups by base catalysed 
transesterification and catalytic hydrogenation, respectively, furnished a series of 3-(β-D-
glucopyranosyl)-5-substituted-1,2,4-triazoles with aliphatic, mono- and bicyclic aromatic, and 
heterocyclic substituents in the 5-position. Enzyme kinetic studies revealed these compounds 
to inhibit rabbit muscle glycogen phosphorylase b: best inhibitors were the 5-(4-
aminophenyl)- (Ki 0.67 µM) and the 5-(2-naphthyl)-substituted (Ki 0.41 µM) derivatives. This 
study uncovered the C-glucopyranosyl-1,2,4-triazoles as a novel skeleton for nanomolar 
inhibition of glycogen phosphorylase. 
Keywords 
1,2,4-Triazole, C-glucopyranosyl derivative, bioisoster, glycogen phosphorylase, inhibitor. 
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1. Introduction 
 
Type 2 diabetes mellitus (T2DM) is a severe disease with large economic consequences, 
which is significantly under-diagnosed and incompletely treated in the general population [1, 
2]. Control of blood glucose levels is a key objective in treating diabetic patients, who are 
most often prescribed modification of diet and exercise, one or more oral hypoglycaemic 
agents, as well as insulin. In spite of the availability of different classes of hypoglycaemic 
drugs, current treatments are often unable to achieve an intensive degree of blood glucose 
control to reduce effectively the incidence and severity of diabetic complications [3].  
Hepatic glucose output is elevated in type 2 diabetic patients and current evidence 
indicates that glycogenolysis (release of monomeric glucose from the glycogen polymer 
storage form) is an important contributor to the abnormally high production of glucose by the 
liver. Glycogen phosphorylase (GP) is the enzyme responsible for glycogen breakdown to 
produce glucose and related metabolites for energy supply [4]. Due to its key role in the 
modulation of glycogen metabolism, pharmacological inhibition of GP has been regarded as 
an effective therapeutic approach to treating diseases caused by abnormalities in glycogen 
metabolism, first of all T2DM [5-7], but also myocardial [8, 9] and cerebral [10, 11] 
ischemias and tumors [12-15]. Therefore, the study of glycogen phosphorylase inhibitors [16] 
(GPIs) is a continuing challenge for synthetic and medicinal chemistry [17, 18], 
computational chemistry [19], protein crystallography [5, 20], and physiology [21]. The 
biochemical and pharmacological background of this research has been thoroughly 
summarized in several reviews of the past decade, therefore, the reader is kindly referred to 
those papers [4, 22, 23]. 
Several structural classes of GP inhibitors have been reported [5, 17, 18, 24] whose 
binding sites identified in GP include the catalytic site, the purine inhibitory site, the allosteric 
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site, the glycogen storage site, the new allosteric inhibitor site and the lately discovered 
benzimidazole-binding site. The most widely studied group of molecules is that of glucose 
derivatives [7, 25-35] which bind primarily to the active site of GP [36]. The best glucose 
analogue GPIs are glucopyranosylidene-spiro-heterocycles (Ki 0.16-0.63 µM) and N-acyl-N’-
β-D-glucopyranosyl ureas (Ki 0.35-0.7 µM) exhibiting submicromolar inhibition [26] of rabbit 
muscle GPb, the prototype of GPs [20]. Glucopyranosylidene-spiro-thiohydantoin (Ki 29.8 
µM against rat liver GP) was shown to exert considerable in vivo blood sugar diminishing 
activity [37], and an N-acyl-N’-β-D-glucopyranosyl urea derivative improved glucose 
tolerance and had remarkable effects in rearranging hepatic metabolism in diabetic mice [38]. 
N-Acyl-β-D-glucopyranosylamines (compounds I in Chart 1) were among the first 
synthetic glucose analogue inhibitors of GP [39] and several derivatives modified in the acyl 
groups were investigated [40-44]. In this series N-(2-naphthoyl)-β-D-glucopyranosylamine 
(IC) was the best inhibitor [41], which also served as a lead structure for bioisosteric 
replacements [45-48]. X-Ray crystallographic studies on several RMGPb-I complexes 
showed the presence of a H-bond between the amide NH and the main chain C=O of His377 
(outline X in Chart 1), and the strong binding was attributed to a large extent to this 
interaction. 
Inserting a 1,2,3-triazole ring in place of the NHCO moiety as in II revealed that I and II 
were equipotent inhibitors [49] and the structural features of the binding determined by X-ray 
crystallography were also very similar [42]. Oxadiazoles III-V, prepared in each possible 
variant [50, 51], showed that the constitution of the heterocycle had a strong bearing on the 
inhibition: the most efficient inhibitor among these compounds was 5-(β-D-glucopyranosyl)-
3-(2-naphthyl)-1,2,4-oxadiazole (IVC) which had a similar efficiency to that of IC. Other 
studies with C-glucopyranosyl heterocycles showed that benzothiazole VI was much less 
efficient than benzimidazoles VII and VIII [33, 52]. An X-ray crystallographic study of the 
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RMGPb–VII complex revealed the presence of a specific H-bond between NH of the 
heterocycle and the main chain C=O of His377 [53] (outline XI in Chart 1), and the stronger 
binding of VII was explained by this interaction which cannot exist in the case of VI.  
Based on these structure–activity relationships it was anticipated that C-glucopyranosyl 
1,2,4-triazoles of type IX, non-classical bioisosteres of compounds I-V, could be more 
efficient GPIs. Very recently we have demonstrated in a preliminary communication that IX 
(R = 2-naphthyl, Ki 0.41 µM) indeed fulfills these expectations [54]. In this paper we disclose 
a new synthesis and structure-activity relationships of IX with a wide range of substituents R.  
 
Chart 1. 
 
In the literature C-glycopyranosyl-1,2,4-triazoles are represented by some 1,3,5-
trisubstituted derivatives obtained from glycosyl cyanides with 1-aza-2-azoniaallene salts [56] 
or with hydrazonoyl chlorides in the presence of Yb(OTf)3 [57]. 3-Glycopyranosyl-5-
substituted-1,2,4-triazoles IX have been unknown until our very recent preliminary 
communication describing the synthesis of these compounds by acylation of N1-tosyl-C-
(2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)formamidrazone followed by N- and/or O-
deprotection [54]. However, this synthetic sequence was rather long (5-6 steps from the 
corresponding glucosyl cyanide) and complicated by the removal of the N-tosyl moiety from 
the heterocycle. Therefore, a more straightforward synthesis of the target compounds has been 
sought for and accomplished by the ring transformation of 5-(2,3,4,6-tetra-O-benzoyl-β-D-
glucopyranosyl)tetrazole.  
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2. Results and Discussion 
 
2.1. Syntheses 
To select a suitable synthetic pathway towards compounds IX a retrosynthetic analysis 
for the construction of the 1,2,4-triazole ring was carried out taking into account 1,3-dipolar 
cycloadditions (Scheme 1). It was envisaged that synthetic methods [58] for 1,3,5-
trisubstituted-1,2,4-triazoles [59, 60] with a protecting group as the 1-substituent could be 
applied. Given the tautomeric nature of this heterocycle three N-protected isomers may exist 
whose disconnections A and B refer to cycloadditions between nitrilimines and nitriles. 
Following route A the known glucosyl cyanide and 2,5-disubstituted-tetrazoles or N-protected 
hydrazones or their halides would have been the necessary starting compounds, however, this 
possibility was ruled out due to the costly reagents and catalysts. For the analogous route B 
precursors of the intermediate C-glucosyl-nitrilimine would have been required which are 
unknown in the literature. Therefore, our attention turned to disconnection C, actually a 
variant of B, which needed the relatively easily available C-glucosyl-tetrazole and imidoyl-
halides. The analogous disconnection C’ (not shown in details) was also discarded because of 
the necessity to prepare a series of tetrazoles and lack of the glucose based precursor of the 
imidoyl-halide. 
 
Scheme 1. 
 
Syntheses of the target compounds were started by the preparation of O-protected C-
glucopyranosyl-tetrazole 1 (Table 1) from 2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl 
cyanide [61] according to our recent procedure [27]. N-Benzyl arenecarboxamides 2, obtained 
from the corresponding acid chloride and benzylamine, were converted to imidoyl chlorides 
by SOCl2 which were then reacted without purification with tetrazole 1 in a one-pot fashion to 
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give 4-benzyl-1,2,4-triazole derivatives 3. The O-benzoyl protecting groups were removed by 
the Zemplén method to give 4. Subsequent catalytic hydrogenation gave fully deprotected C-
glucopyranosyl-1,2,4-triazoles 6d-g,i,m,p,q. Several O-perbenzoylated 3-glucopyranosyl-5-
substituted derivatives 5 were obtained in an alternative synthetic pathway published recently 
[62], and these compounds were also converted to the corresponding unprotected 6a-
d,h,j,l,n,q,r by the Zemplén protocol. Amino compounds 6k and 6o were obtained from the 
corresponding nitro derivatives 6j and 6n, respectively, by catalytic hydrogenation.  
 
Table 1. 
 
 
2.2. Enzyme kinetic studies 
The new compounds were assayed against rabbit muscle glycogen phosphorylase b as 
described in earlier publications [40, 63], and the results are collected in Table 2.  
Compounds 6a-c with aliphatic substituents proved weak inhibitors and were much less 
efficient than the corresponding „parent” amides I (shown in Chart 1; for R = CH3: Ki 32 µM 
[39]; R = C(CH3)3: IC50 7.5 mM [41]; R = CH2OH: Ki 18 [42] or 20 [49] µM), however, the 
trend in the strength of inhibition remained the same (t-butyl derivatives were the less 
efficient followed by the methyl and hydroxymethyl compounds in both series).  
Appending a phenyl substituent to the heterocycle as in 6d resulted in a significantly 
better inhibitor. A comparison to the corresponding amide I (R = C6H5: Ki 81 [39] or 144 
[40]) indicated more than an order of magnitude stronger inhibition by the triazole, and this 
strengthening was higher than those observed with the aliphatic amide-triazole pairs. 
Introduction of substituents in the 4-position of the phenyl ring brought about large changes in 
the inhibition. The 4-tolyl derivative 6e was ~4 times better than 6d, and comparing it to the 
relevant amide I (R = 4-CH3-C6H4: IC50 4.5 mM [41]) revealed a very large increase of the 
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binding strength in favour of the triazole. The bulky 4-t-butyl substituent in 6f caused a 
significant weakening of the inhibition. The 4-trifluoromethyl derivative 6g proved also a 
weak inhibitor, and this was surprising especially in the light of the similar size of CH3 (6e) 
and CF3 (6g). The presence of a phenolic hydroxyl group in position 4 (6h) made again a 
good inhibitor, and the 4-methoxy compound 6i proved slightly better and comparable to 6e. 
Introduction of the 4-nitro substituent weakened the binding in comparison to 6d, however, 
the 4-amino derivative 6k was inhibiting in the submicromolar range. This may reveal the 
significance of a basic group in making contacts to the relevant parts of the enzyme. A 
carboxylic acid function in the 4-position (6l) was fully detrimental for the binding and this 
may be at least in part due to the size of this group (compare with the slightly acidic 6h).  
Multiple substitutions in the phenyl ring (6m-p) resulted in generally weaker inhibitors, 
although the importance of the basic substituents was corroborated by the diamino derivative 
6o showing the highest efficiency within this group of inhibitors.  
The 2-naphthyl compound 6q proved the best inhibitor of the whole series, and its 
nanomolar inhibition constant rendered this derivative among the most efficient glucose 
analogue inhibitors of GP. Comparing 6q to the corresponding amide I (R = 2-naphthyl: Ki 10 
[41] or 13 [42]) indicates a ~25-30-fold stronger binding for the triazole.  
The 2-pyridyl moiety of 6r was disadvantegous for the inhibition (a similar tendency was 
observed in the N-acyl-N’-β-D-glucopyranosyl urea series [24]).  
A comparison of the inhibitory potency of these triazole derivatives clearly shows them 
to be superior to the corresponding oxadiazoles (III-V in Chart 1), as well. For the directly 
comparable pairs of 1,2,4-triazoles 6 and the best 1,2,4-oxadiazoles IV the increase of the 
efficiency is in the 9-29-fold range for the phenyl and 2-naphthyl substituted derivatives, 
respectively. 
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Further studies to understand the binding peculiarities of this series of GPIs by molecular 
dockings and X-ray crystallography are in progress and will be disclosed in due course. 
 
Table 2. 
 
 
3. Conclusion 
 
A new synthetic sequence has been elaborated for the preparation of 3-(β-D-
glucopyranosyl)-5-substituted-1,2,4-triazoles by converting 5-(2,3,4,6-tetra-O-benzoyl-β-D-
glucopyranosyl)tetrazole with N-benzyl carboximidoyl chlorides into O-perbenzoylated 4-
benzyl-3-(β-D-glucopyranosyl)-5-substituted-1,2,4-triazoles and subsequent O- and N-
deprotection. These triazole derivatives with aliphatic, phenyl, substituted phenyl, 2-naphthyl, 
and 2-pyridyl substituents in the 5-position were evaluated as inhibitors of rabbit muscle 
glycogen phosphorylase b. Compounds with aliphatic groups exhibited weak inhibition, while 
several phenyl derivatives were low micromolar inhibitors. Nanomolar inhibition was 
observed for the 5-(4-aminophenyl)- and the 5-(2-naphthyl)-substituted compounds of the 
series rendering these derivatives to be among the best glucose derived GPIs with similar 
efficiency as those of glucopyranosylidene-spiro-heterocycles and N-acyl-N’-β-D-
glucopyranosyl ureas.  
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4. Experimental 
 
4.1. General methods 
Melting points were measured on a Kofler hot-stage and are uncorrected. Optical rotations 
were determined with a Perkin–Elmer 241 polarimeter at rt. NMR spectra were recorded with 
Bruker 360 (360/90 MHz for 1H/ 13C) spectrometer. Chemical shifts are referenced to Me4Si 
(1H), or to the residual solvent signals (13C). Mass spectra were recorded on a Bruker Micro 
TOF-Q mass spectrometer. Microanalyses were performed on an Elementar Vario Micro 
Cube. TLC was performed on DC-Alurolle Kieselgel 60 F254 (Merck), and the plates were 
visualised under UV light and by gentle heating. For column chromatography Kieselgel 60 
(Merck, particle size 0.063–0.200 mm) was used. 5-(2’,3’,4’,6’-Tetra-O-benzoyl-β-D-
glucopyranosyl)tetrazole [27] (1) and 5-substituted-3-(2’,3’,4’,6’-tetra-O-benzoyl-β-D-
glucopyranosyl)-1,2,4-triazoles [62] 5a,b,d,j,n,q,r,t,u were prepared according to published 
procedures.  
 
4.2. General procedure I for the synthesis of N-benzyl-arenecarboxamides (2) 
In a flame dried three necked bottle, equipped with a CaCl2 tube, benzylamine (1 mL, 9.16 
mmol) and TEA (1.53 mL, 11 mmol, 1.2 equiv.) was dissolved in the appropriate anhydrous 
solvent (5 mL, CH2Cl2, THF or toluene, depending on the solubility of acid chloride). To this 
stirred mixture a solution (in 5 mL anhydrous CH2Cl2, THF or toluene) of an acid chloride 
(9.16 mmol, 1 equiv.) was added dropwise at 0°C. The mixture was slowly allowed to reach 
rt, stirred for 2 hours, then diluted, and extracted with water. The organic phase was dried 
over MgSO4, the solvent was evaporated, and the crude product was crystallised from EtOH. 
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Yields of the synthesized derivatives: N-benzyl-benzamide [65] (2d, 64 %), N-benzyl-4-
methylbenzamide [66] (2e, 81 % ), N-benzyl-4-tert-butylbenzamide [67] (2f, 97 %), N-
benzyl-4-trifluoromethylbenzamide [68] (2g, 76 %), N-benzyl-4-methoxybenzamide [66] (2i, 
67 %), N-benzyl-4-nitrobenzamide [69] (2j, 77 % ), N-benzyl-3,5-dimethylbenzamide [67] 
(2m, 81 %), N-benzyl-3,4,5-trimethoxybenzamide [70] (2p, 98 %), N-benzyl-naphthalene-2-
carboxamide [71] (2q, 74 %), N-benzyl-(4-benzyloxycarbonyl)-benzamide (2s, 56%, mp: 
127-129 °C). Physical as well as NMR data of the title compounds are in agreement with 
those reported in the cited literature. 
 
4.3. General procedure II for the synthesis of 4-benzyl-3-(2’,3’,4’,6’-tetra-O-benzoyl-β-D-
glucopyranosyl)-5-substituted-1,2,4-triazoles (3) 
An N-benzyl-arenecarboxamide (2, 4.63 mmol, 3 equiv.) was dissolved in thionyl chloride 
(20 mL), and refluxed for 2 hours. After distilling off the excess of thionyl chloride under 
diminished pressure, 20 mL of anhydrous toluene was evaporated from the residue. 5-
(2’,3’,4’,6’-Tetra-O-benzoyl-β-D-glucopyranosyl)tetrazole[27, 52] (1, 1.54 mmol, 1 equiv.) 
and anhydrous toluene or xylene (20 mL) were added, the mixture was heated to reflux 
temperature, and the reaction was monitored by TLC (1:1 EtOAc-hexane). After total 
consumption of the tetrazole the solvent was removed and the residue was purified by column 
chromatography. 
 
4.4. General procedure III for removal of O-acyl protecting groups by the Zemplén 
protocol 
An O-acylated compound was dissolved in dry MeOH (5 mL/100 mg, a few drops of CHCl3 
were added in case of incomplete dissolution) and a catalytic amount of a NaOMe solution (1 
M in MeOH) was added. The mixture was kept at rt and monitored by TLC (7:3 CHCl3-
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MeOH). When the starting material was consumed the mixture was neutralised with a cation 
exchange resin Amberlyst 15 (H+ form) (or with acetic acid), then the resin was filtered off 
and the solvent removed. The residue was purified by column chromatography. 
 
4.5. General procedure IV for the removal of benzyl protecting groups 
A benzylated compound (0.5 mmol) was dissolved in anhydrous MeOH (25 mL), 10% Pd(C) 
(20 mg) was added, and H2 gas was bubbled through the reaction mixture at 50°C. After 
disappearance of the starting material (monitored by TLC, 7:3 CHCl3-MeOH) the reaction 
mixture was filtered through a pad of celite, the solvent was evaporated, and the residue was 
purified by column chromatography. 
 
4.6. 4-Benzyl-5-phenyl-3-(2’,3’,4’,6’-tetra-O-benzoyl-β-D-glucopyranosyl)-1,2,4-triazole 
(3d) 
From tetrazole 1 (2.00 g, 3.08 mmol) and N-benzyl-benzamide (2d, 1.95 g, 9.25 mmol) in 
toluene according to General procedure II. Reaction time: 16 hours. Purified by column 
chromatography (1:1 EtOAc-hexane) to yield 1.73 g (69 %) colourless syrup. Rf: 0.15 (1:1 
EtOAc-hexane); [α]D = −25 (c 0.50, CHCl3); 1H NMR (CDCl3) δ (ppm): 7.95-6.97 (30H, m 
aromatics), 5.99-5.96 (2 x 1H, m, H-2’ and/or H-3’ and/or H-4’), 5.67 (1H, pseudo t, J = 10.6, 
9.3 Hz, H-2’ or H-3’ or H-4’), 5.63 (1H, d, J = 15.9 Hz, PhCH2), 5.53 (1H, d, J = 15.9 Hz, 
PhCH2), 5.16 (1H, d, J = 9.3 Hz, H-1’), 4.49 (1H, dd, J = 12.2, 2.4 Hz, H-6’a), 4.33 (1H, dd, J 
= 12.2, 5.4 Hz, H-6’b), 4.19 (1H, ddd, J = 9.6, 5.4, 2.4 Hz, H-5’); 13C NMR (CDCl3) δ (ppm): 
165.9, 165.7, 165.1, 164.8 (CO), 156.7, 149.8 (triazole C-3, C-5), 135.4-126.2 (aromatics), 
76.8, 73.8, 73.2, 70.0, 69.1 (C-1’ – C-5’), 62.9 (C-6’), 48.1 (PhCH2). Anal: Calcd for 
C49H39N3O9 (813.85): C, 72.31; H, 4.83; N, 5.16. Found: C, 72.47; H, 4.88; N, 5.03. 
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4.7. 4-Benzyl-5-(4-methylphenyl)-3-(2’,3’,4’,6’-tetra-O-benzoyl-β-D-glucopyranosyl)-
1,2,4-triazole (3e) 
From tetrazole 1 (0.50 g, 0.77 mmol) and N-benzyl-4-methylbenzamide (2e, 0.52 g, 2.31 
mmol) in m-xylene according to General procedure II. Reaction time: 3 hours. Purified by 
column chromatography (1:1 EtOAc-hexane) to yield 0.32 g (49 %) brownish foam. Rf: 0.20 
(1:1 EtOAc-hexane); [α]D = −4 (c 0.50, CHCl3); 1H NMR (CDCl3) δ (ppm): 7.97-6.98 (29H, 
m, aromatics), 6.04, 5.98, 5.68 (3 x 1H, 3 pseudo t, J = 9.5, 9.5 Hz in each, H-2’, H-3’, H-4’), 
5.50 (1H, d, J = 16.5 Hz, PhCH2), 5.31 (1H, d, J = 16.5 Hz, PhCH2), 5.13 (1H, d, J = 9.5 Hz, 
H-1’), 4.48 (1H, dd, J = 12.4, 2.6 Hz, H-6’a), 4.34 (1H, dd, J = 12.4, 5.4 Hz, H-6’b), 4.20 
(1H, ddd, J = 9.8, 5.4, 2.6 Hz, H-5’), 2.33 (3H, s, CH3); 13C NMR (CDCl3) δ (ppm): 165.8, 
165.7, 165.0, 164.6 (CO), 156.7, 149.7 (triazole C-3, C-5), 140.2, 135.4, 133.4-123.6 
(aromatics), 76.6, 73.8, 73.0, 69.9, 69.0 (C-1’ – C-5’), 62.8 (C-6’), 47.9 (PhCH2), 21.3 (CH3). 
Anal: Calcd for C50H41N3O9 (827.88): C, 72.54; H, 4.99; N, 5.08. Found: C, 72.65; H, 4.88; 
N, 5.20. 
 
4.8. 4-Benzyl-5-(4-tert-butylphenyl)-3-(2’,3’,4’,6’-tetra-O-benzoyl-β-D-glucopyranosyl)-
1,2,4-triazole (3f)  
From tetrazole 1 (0.70 g, 1.08 mmol) and N-benzyl-4-tert-butylbenzamide (2f, 0.93 g, 3.23 
mmol) in m-xylene according to General procedure II. Reaction time: 3 hours. Purified by 
column chromatography (1:1 EtOAc-hexane) to yield 0.57 g (61 %) yellow solid. Mp: 231-
233 °C; Rf: 0.28 (1:1 EtOAc-hexane); [α]D = −43 (c 0.37, CHCl3);1H NMR (CDCl3) δ (ppm): 
7.97-7.00 (29H, m, aromatics), 6.00, 5.97, 5.65 (3 x 1H, 3 pseudo t, J = 9.6, 9.6 Hz in each, 
H-2’, H-3’, H-4’), 5.51 (1H, d, J = 16.5 Hz, PhCH2), 5.33 (1H, d, J = 16.5 Hz, PhCH2), 5.11 
(1H, d, J = 9.6 Hz, H-1’), 4.49 (1H, dd, J =12.2, 1.9 Hz, H-6’a), 4.32 (1H, dd, J =12.2, 5.3 
Hz, H-6’b), 4.17 (1H, ddd, J =9.6, 5.2, 1.9 H-5’), 1.29 (9H, s, C(CH3)3); 13C NMR (CDCl3) δ 
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(ppm): 165.9, 165.7, 165.1, 164.7 (CO), 156.7, 153.4 (triazole C-3, C-5), 149.7, 135.5, 133.5-
123.7 (aromatics), 76.7, 73.9, 73.1, 69.9, 69.1 (C-1’ – C-5’), 62.9 (C-6’), 48.0 (PhCH2), 34.2 
(C(CH3)3), 31.1 (C(CH3)3). Anal: Calcd for C53H47N3O9 (869.95): C, 73.17; H, 5.45; N, 4.83. 
Found: C, 73.11; H, 5.36; N, 4.91. 
 
4.9. 4-Benzyl-5-(4-trifluoromethylphenyl)-3-(2’,3’,4’,6’-tetra-O-benzoyl-β-D-
glucopyranosyl)-1,2,4-triazole (3g) 
From tetrazole 1 (0.60 g, 0.93 mmol) and N-benzyl-4-trifluoromethylbenzamide (2g, 0.78 g, 
2.78 mmol) in toluene according to General procedure II. Reaction time: 16 hours. Purified 
by column chromatography (1:4 → 1:1 EtOAc-hexane) to yield 0.72 g (88 %) white solid. 
Mp: 213-215 °C; [α]D = −26 (c 0.54, CHCl3); 1H NMR (CDCl3) δ (ppm): 7.94-6.95 (29H, m, 
aromatics), 6.06-5.98 (2 x 1H, m, H-2’ and/or H-3’ and/or H-4’), 5.70 (1H, pseudo t, J = 9.2, 
9.2 Hz, H-2’ or H-3’ or H-4’), 5.60 (1H, d, J = 16.4 Hz, PhCH2), 5.29 (1H, d, J = 16.4 Hz, 
PhCH2), 5.21 (1H, d, J = 8.8 Hz, H-1’), 4.50 (1H, dd, J = 12.3, < 1 Hz, H-6’a), 4.34 (1H, dd, J 
= 12.3, 4.8 Hz, H-6’b), 4.23 (1H, ddd, J = 9.2, 4.8, < 1 Hz, H-5’); 13C NMR (CDCl3) δ (ppm): 
165.8, 165.7, 165.1, 164.8 (CO), 155.4, 150.3 (triazole C-3, C-5), 134.9-125.0 (aromatics), 
132.0 (q, 2J(C, F) = 34.6 Hz, C-CF3), 123.5 (q, 1J(C, F) = 271.3 Hz, CF3), 76.8, 73.7, 73.2, 69.9, 
68.9 (C-1’ – C-5’), 62.7 (C-6’), 48.2 (PhCH2). Anal: Calcd for C50H38F3N3O9 (881.85): C, 
68.10; H, 4.34; N, 4.77. Found: C, 68.23; H, 4.41; N, 4.63. 
 
4.10. 4-Benzyl-5-(4-methoxyphenyl)-3-(2’,3’,4’,6’-tetra-O-benzoyl-β-D-glucopyranosyl)-
1,2,4-triazole (3i) 
From tetrazole 1 (1.0 g, 1.54 mmol) and N-benzyl-4-methoxybenzamide (2i, 1.12 g, 4.64 
mmol) in m-xylene according to General procedure II. Purified by column chromatography 
(1:1 → 2:1 EtOAc-hexane) to yield 0.81 g (62 %) white amorphous solid. Rf: 0.45 (2:1 
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EtOAc-hexane); [α]D = −19 (c 0.55, CHCl3); 1H NMR (CDCl3) δ (ppm): 7.98-6.98 (27H, m, 
aromatics); 6.87 (2H, d, J = 8.8 Hz, aromatics), 6.06-5.91 (2 x 1H, m, H-2’ and/or H-3’ and/or 
H-4’), 5.65 (1H, pseudo t, J = 9.6, 9.6 Hz, H-2’ or H-3’ or H-4’), 5.50 (1H, d, J =16.6 Hz, 
PhCH2), 5.29 (1H, d, J = 16.6 Hz, PhCH2), 5.18 (1H, d, J = 9.6, H-1’), 4.48 (1H, dd, J = 12,3, 
2.6 Hz, H-6’a), 4.32 (1H, dd, J = 12,3 and 5.4 Hz, H-6’b), 4.19 (1H, ddd, J = 9.6, 5.4, 2.6 Hz, 
H-5’), 3.79 (3H, s, OMe); 13C NMR (CDCl3) δ (ppm): 166.0, 165.8, 165.2, 164.8 (CO), 161.1 
(MeOPh C-4), 156.7, 149.7 (triazole C-3, C-5), 135.5-126.1, 118.8, 114.2 (2) (aromatics), 
76.7, 73.9, 73.2, 70.0, 69.1 (C-1’ – C-5’), 63.0 (C-6’), 55.3 (OMe), 48.1 (PhCH2). Anal: 
Calcd for C50H41N3O10 (843.87): C, 71.16; H, 4.90; N, 4.98. Found: C, 71.08; H, 5.01; N, 
4.91. 
 
4.11. 4-Benzyl-5-(4-nitrophenyl)-3-(2’,3’,4’,6’-tetra-O-benzoyl-β-D-glucopyranosyl)-
1,2,4-triazole (3j) 
From tetrazole 1 (0.50 g, 0.77 mmol) and N-benzyl-4-nitrobenzamide (2j, 0.59 g, 2.31 mmol) 
in toluene according to General procedure II. Reaction time: 16 hours. Purified by column 
chromatography (1:1 EtOAc-hexane) to yield 0.25 g (38 %) yellow syrup. Rf: 0.28 (1:1 
EtOAc-hexane); [α]D = −41 (c 0.50, CHCl3); 1H NMR (CDCl3) δ (ppm): 8.18 (2H, d, J = 8.5 
Hz, aromatics), 7.92-7.19 (25H, m, aromatics), 6.95 (2H, d, J = 6.9 Hz, aromatics), 6.05, 6.00, 
5.72 (3 x 1H, 3 pseudo t, J = 9.5, 9.5 Hz in each, H-2’, H-3’, H-4’), 5.66 (1H, d, J = 16.5 Hz, 
PhCH2), 5.31 (1H, d, J = 16.5 Hz, PhCH2), 5.26 (1H, d, J = 9.4 Hz, H-1’), 4.51 (1H, dd, J = 
12.1, < 1 Hz, H-6’a), 4.35 (1H, dd, J = 12.1, 5.1 Hz, H-6’b), 4.27 (1H, ddd, J = 9.5, 5.1, 2.2 
Hz, H-5’); 13C NMR (CDCl3) δ (ppm): 165.8, 165.6, 165.1, 164.9 (CO), 154.6, 150.7 (triazole 
C-3, C-5), 148.6, 134.6-123.7 (aromatics), 76.8, 73.6, 73.2, 70.1, 68.9 (C-1’ – C-5’), 62.7 (C-
6’), 48.4 (PhCH2). Anal: Calcd for C49H38N4O11 (858.85): C, 68.52; H, 4.46; N, 6.52. Found: 
C, 68.64; H, 4.52; N, 6.43. 
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4.12. 4-Benzyl-5-(3,5-dimethylphenyl)-3-(2’,3’,4’,6’-tetra-O-benzoyl-β-D-
glucopyranosyl)-1,2,4-triazole (3m) 
From tetrazole 1 (1.0 g, 1.54 mmol) and N-benzyl-3,5-dimethylbenzamide (2m, 1.11 g, 4.64 
mmol) in m-xylene according to General procedure II. Reaction time: 3 hours. Purified by 
column chromatography (1:1 → 2:1 EtOAc-hexane) to yield 0.85 g (66 %) white solid. Mp: 
225-227 °C; Rf: 0.28 (1:1 EtOAc-hexane); [α]D = −19 (c 0.37, CHCl3); 1H NMR (CDCl3) δ 
(ppm): 7.98-7.00 (28H, m, aromatics), 6.12, 6.05, 5.75 (3 x 1H, 3 pseudo t, J = 9.5, 9.3 Hz in 
each, H-2’, H-3’, H-4’), 5.50 (1H, d, J = 16.4 Hz, PhCH2), 5.32 (1H, d, J = 16.4 Hz, PhCH2), 
5.22 (1H, d, J = 9.6 Hz, H-1’), 4.52 (1H, dd, J = 12.5, 2.6 Hz, H-6’a), 4.39 (1H, dd, J = 12.6, 
5.2 Hz, H-6’b), 4.26 (1H, ddd, J = 9.5, 5.2, 2.6 Hz, H-5’), 2.19 (6H, s, 2 x CH3); 13C NMR 
(CDCl3) δ (ppm): 165.6, 165.5, 164.9, 164.5 (CO), 156.7, 149.6 (triazole C-3, C-5), 138.0 (2), 
135.3-126.0 (aromatics), 76.4, 73.8, 72.6, 69.8, 68.8 (C-1’ – C-5’), 62.6 (C-6’), 47.9 (PhCH2), 
20.9 (2 x CH3). Anal: Calcd for C51H43N3O9 (841.90): C, 72.76; H, 5.15; N, 4.99. Found: C, 
72.69; H, 5.07; N, 4.86. 
 
4.13. 4-Benzyl-5-(3,4,5-trimethoxyphenyl)-3-(2’,3’,4’,6’-tetra-O-benzoyl-β-D-
glucopyranosyl)-1,2,4-triazole (3p) 
From tetrazole 1 (0.50 g, 0.77 mmol) and N-benzyl-3,4,5-trimethoxybenzamide (2p, 0.7 g, 
2.31 mmol) in m-xylene according to General procedure II. Reaction time: 8 hours. Purified 
by column chromatography (3:2 EtOAc-hexane) to yield 0.45 g (65 %) pale yellow syrup. Rf: 
0.15 (3:2 EtOAc-hexane); [α]D = −33 (c 0.60, CHCl3); 1H NMR (CDCl3) δ (ppm): 7.96-7.00 
(25H, m, aromatics), 6.62 (2H, s, aromatics), 6.10-5.99 (2 x 1H, m, H-2’ and/or H-3’ and/or 
H-4’), 5.70 (1H, pseudo t, J = 9.3, 9.3 Hz, H-2’ or H-3’ or H-4’), 5.55 (1H, d, J = 16.8 Hz, 
PhCH2), 5.31 (1H, d, J = 16.8 Hz, PhCH2), 5.22 (1H, d, J = 9.3 Hz, H-1’), 4.45 (1H, dd, J = 
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10.8, < 1 Hz, H-6’a), 4.32-4.24 (2 x 1H, m, H-6’b, H-5’), 3.83 (3H, s, OMe), 3.59 (6H, s, 2 x 
OMe); 13C NMR (CDCl3) δ (ppm): 165.8, 165.7, 165.0, 164.7 (CO), 156.5, 153.2, 150.0 
(triazole C-3, C-5, 3,4,5-(MeO)3Ph C-3, C-5), 135.7-121.5, 106.1 (2) (aromatics), 76.7, 73.8, 
73.1, 70.0, 68.9 (C-1’ – C-5’), 62.8 (C-6’), 60.8 (OMe), 55.8 (2 x OMe), 48.1 (PhCH2). Anal: 
Calcd for C52H45N3O12 (903.93): C, 69.09; H, 5.02; N, 4.65. Found: C, 69.19; H, 4.96; N, 
4.51. 
 
4.14. 4-Benzyl-5-(2-naphthyl)-3-(2’,3’,4’,6’-tetra-O-benzoyl-β-D-glucopyranosyl)-1,2,4-
triazole (3q) 
From tetrazole 1 (0.60 g, 0.93 mmol) and N-benzyl-naphthalene-2-carboxamide (2q, 0.73 g, 
2.78 mmol) in toluene according to General procedure II. Reaction time: 3 hours. Purified by 
column chromatography (1:1 → 3:2 EtOAc-hexane) to yield 0.41 g (52 %) pale yellow 
amorphous solid. Rf: 0.25 (1:1 EtOAc-hexane); [α]D = −33 (c 0.50, CHCl3); 1H NMR (CDCl3) 
δ (ppm): 7.96-7.01 (32H, m, aromatics), 6.08, 6.02, 5.70 (3 x 1H, 3 pseudo t, J = 9.3, 9.3 Hz 
in each, H-2’, H-3’, H-4’), 5.58 (1H, d, J = 15.9 Hz, PhCH2), 5.38 (1H, d, J = 15.9 Hz, 
PhCH2), 5.19 (1H, d, J = 9.3 Hz, H-1’), 4.49 (1H, dd, J = 11.9, 2.6 Hz, H-6’a), 4.35 (1H, dd, J 
= 11.9, 5.3 Hz, H-6’b), 4.23 (1H, ddd, J = 9.3, 5.3, 2.6 Hz, H-5’); 13C NMR (CDCl3) δ (ppm): 
165.8, 165.7, 165.0, 164.7 (CO), 156.6, 149.9 (triazole C-3, C-5), 135.4-123.9 (aromatics), 
76.7, 73.8, 73.0, 69.9, 69.0 (C-1’ – C-5’), 62.8 (C-6’), 48.2 (PhCH2). Anal: Calcd for 
C53H41N3O9 (863.91): C, 73.68; H, 4.78; N, 4.86. Found: C, 73.80; H, 4.69; N, 4.97. 
 
4.15. 4-Benzyl-5-(4-benzyloxycarbonylphenyl)-3-(2’,3’,4’,6’-tetra-O-benzoyl-β-D-
glucopyranosyl)-1,2,4-triazole (3s) 
From tetrazole 1 (0.30 g, 0.46 mmol) and N-benzyl-(4-benzyloxycarbonyl)-benzamide (2s, 
0.48 g, 1.39 mmol) in m-xylene according to General procedure II. Reaction time: 3 hours. 
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Purified by column chromatography (1:4 → 1:1 EtOAc-hexane) to yield 0.30 g (69 %) 
brownish foam. Rf: 0.23 (1:1 EtOAc-hexane); [α]D = −26 (c 0.54, CHCl3); 1H NMR (CDCl3) 
δ (ppm): 8.07-6.94 (34H, m, aromatics), 6.01-5.99 (2 x 1H, m, H-2’ and/or H-3’ and/or H-4’), 
5.68 (1H, pseudo t, J = 9.4, 8.6 Hz, H-2’ or H-3’ or H-4’), 5.57 (1H, d, J = 16.5 Hz, PhCH2), 
5.35 (2H, s, PhCH2), 5.29 (1H, d, J = 16.5 Hz, PhCH2), 5.18 (1H, d, J = 9.2 Hz, H-1’), 4.49 
(1H, dd, J = 12.3, 2.0 Hz, H-6’a), 4.33 (1H, dd, J = 12.3, 5.3 Hz, H-6’b), 4.20 (1H, ddd, J = 
9.5, 5.3, 2.0 Hz, H-5’); 13C NMR (CDCl3) δ (ppm): 165.8, 165.7, 165.5, 165.0, 164.8 (CO), 
155.8, 150.3 (triazole C-3, C-5), 135.6-126.0 (aromatics), 76.8, 73.7, 73.2, 70.0, 68.9 (C-1’ – 
C-5’), 67.0 (COOCH2Ph), 62.8 (C-6’), 48.2 (PhCH2). Anal: Calcd for C57H45N3O11 (947.98): 
C, 72.22; H, 4.78; N, 4.43. Found: C, 72.28; H, 4.91; N, 4.34. 
 
4.16. 4-Benzyl-3-(β-D-glucopyranosyl)-5-phenyl-1,2,4-triazole (4d) 
From triazole 3d (0.82 g, 1.00 mmol) according to General procedure III. Reaction time: 4 
days. Purified by column chromatography (9:1 → 4:1 CHCl3-MeOH) to yield 0.29 g (73 %) 
pale yellow syrup. Rf: 0.55 (7:3 CHCl3-MeOH); [α]D = −15 (c 0.60, MeOH); 1H NMR (D2O) 
δ (ppm): 7.50-6.94 (10H, m, aromatics), 5.31 (2H, s, PhCH2), 4.48 (1H, d, J = 10.6 Hz, H-1’), 
3.98 (1H, pseudo t, J = 9.3, 9.3 Hz, H-2’ or H-3’ or H-4’), 3.67-3.47 (4 x 1H, m, H-6’a, H-
6’b, H-2’ and/or H-3’ and/or H-4’), 3.34 (1H, m, H-5’); 13C NMR (D2O) δ (ppm): 156.9, 
153.2 (triazole C-3, C-5), 135.2, 131.2, 129.3 (2), 129.1 (2), 129.0 (2), 128.3, 126.4 (2), 125.4 
(aromatics), 80.3, 77.2, 72.1, 71.8, 69.4 (C-1’ – C-5’), 60.8 (C-6’), 47.6 (PhCH2). Anal: Calcd 
for C21H23N3O5 (397.42): C, 63.46; H, 5.83; N, 10.57. Found: C, 63.32; H, 5.75; N, 10.68. 
 
4.17. 4-Benzyl-3-(β-D-glucopyranosyl)-5-(4-methylphenyl)-1,2,4-triazole (4e) 
From triazole 3e (0.52 g, 0.63 mmol) according to General procedure III. Reaction time: 2 
days. Purified by column chromatography (9:1 → 4:1 CHCl3-MeOH) to yield 0.25 g (94 %) 
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colourless syrup. Rf: 0.35 (4:1 CHCl3-MeOH); [α]D = −4 (c 0.50, MeOH); 1H NMR (CD3OD) 
δ (ppm): 7.34-7.23 (7H, m, aromatics), 7.00 (2H, d, J = 6.6 Hz, aromatics), 5.41 (1H, d, J = 
16.9 Hz, PhCH2), 5.34 (1H, d, J = 16.9 Hz, PhCH2), 4.34 (1H, d, J = 9.7 Hz, H-1’), 3.92 (1H, 
pseudo t, J = 9.1, 8.9 Hz, H-2’ or H-3’ or H-4’), 3.75 (1H, dd, J = 12.0, < 1 Hz, H-6’a), 3.63-
3.54 (2H, m, H-6’b, H-2’ or H-3’ or H-4’) 3.43-3.72 (2H, m, H-2’ or H-3’ or H-4’, H-5’), 
2.34 (3H, s, CH3); 13C NMR (CD3OD) δ (ppm): 157.4, 155.0 (triazole C-3, C-5), 142.4, 
136.9, 130.7 (2), 130.1 (2), 130.0 (2), 129.2, 127.5(2), 124.7 (aromatics), 82.5, 79.3, 74.2, 
73.6, 71.1 (C-1’ – C-5’), 62.7 (C-6’), 47.7 (PhCH2), 21.5 (CH3). Anal: Calcd for C22H25N3O5 
(411.45): C, 64.22; H, 6.12; N, 10.21. Found: C, 64.37; H, 6.19; N, 10.10. 
 
4.18. 4-Benzyl-3-(β-D-glucopyranosyl)-5-(4-tert-butylphenyl)-1,2,4-triazole (4f)  
From triazole 3f (0.49 g, 0.56 mmol) according to General procedure III. Reaction time: 1 
day. Purified by column chromatography (4:1 CHCl3-MeOH) to yield 0.25 g (98 %) yellow 
syrup. Rf: 0.31 (4:1 CHCl3-MeOH); [α]D = −3 (c 0.31, MeOH); 1H NMR (CD3OD) δ (ppm): 
7.45 (2H, d, J = 8.3 Hz, aromatics), 7.35 (2H, d, J =8.3 Hz, aromatics), 7.23 (3H, m, 
aromatics), 6.99 (2H, d, J = 6.4 Hz, aromatics), 5.40 (1H, d, J = 16.8 Hz, PhCH2), 5.33 (1H, 
d, J = 16.8 Hz, PhCH2), 4.31 (1H, d, J = 9.7 Hz, H-1’), 3.89 (1H, pseudo t, J = 9.4, 9.0 Hz, H-
2’ or H-3’ or H-4’), 3.74 (1H, dd, J = 12.1, 2.6 Hz, H-6’a), 3.56 (1H, dd, J = 12.1, 5.3 Hz, H-
6’b), 3.41-3.34 (2H, m, H-2’ and/or H-3’ and/or H-4’), 3.25 (1H, ddd, J = 9.8, < 1 Hz, H-5’), 
1.27 (9H, s, C(CH3)3), 13C NMR (CD3OD) δ (ppm): 157.3, 155.4, 155.1 (triazole C-3, C-5, 4-
tBuPh C-4), 136.9-124.7 (aromatics), 82.5, 79.3, 74.2, 73.6, 71.1 (C-1’ – C-5’), 62.7 (C-6’), 
48.7 (PhCH2), 35.8 (C(CH3)3), 31.6 (C(CH3)3). Anal: Calcd for C25H31N3O5 (453.53): C, 
66.21; H, 6.89; N, 9.27. Found: C, 66.27; H, 6.78; N, 9.39. 
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4.19. 4-Benzyl-3-(β-D-glucopyranosyl)-5-(4-trifluoromethylphenyl)-1,2,4-triazole (4g) 
From triazole 3g (0.50 g, 0.57 mmol) according to General procedure III. Reaction time: 4 
hours. Purified by column chromatography (4:1 CHCl3-MeOH) to yield 0.16 g (61 %) white 
crystals. Mp: 208-210 °C; [α]D = −18 (c 0.48, MeOH); 1H NMR (CD3OD) δ (ppm): 7.77-7.05 
(9H, m, aromatics), 5.51 (1H, d, J = 16.9 Hz, PhCH2), 5.45 (1H, d, J = 16.9 Hz, PhCH2), 4.48 
(1H, d, J = 9.3 Hz, H-1’), 3.99 (1H, m, H-2’ or H-3’ or H-4’), 3.82 (1H, dd, J = 11.7, < 1 Hz, 
H-6’a), 3.65 (1H, dd, J = 11.7, < 1 Hz, H-6’b), 3.47-3.37 (3 x 1H, m, H-2’ and/or H-3’ and/or 
H-4’, H-5’); 13C NMR (CD3OD) δ (ppm): 156.0, 155.6 (triazole C-3, C-5), 136.6 (aromatics), 
133.4 (q, 2J(C, F) = 31.7 Hz, C-CF3), 131.7-127.0 (aromatics), 125.2 (q, 1J(C, F) = 271.3 Hz, 
CF3), 82.5, 79.3, 74.2, 73.6, 71.1 (C-1’ – C-5’), 62.7 (C-6’), 48.9 (PhCH2). Anal: Calcd for 
C22H22F3N3O5 (465.42): C, 56.77; H, 4.76; N, 9.03. Found: C, 56.69; H, 4.71; N, 9.14. 
 
4.20. 4-Benzyl-3-(β-D-glucopyranosyl)-5-(4-methoxyphenyl)-1,2,4-triazole (4i) 
From triazole 3i (0.80 g, 0.95 mmol) according to General procedure III. Reaction time: 3 
hours. Purified by column chromatography (4:1 CHCl3-MeOH) to yield 0.23 g (68 %) yellow 
syrup. Rf: 0.33 (4:1 CHCl3-MeOH). [α]D = −14 (c 0.35, MeOH); 1H NMR (CD3OD) δ (ppm): 
7.37 (2H, d, J = 8.8 Hz, aromatics), 7.32-7.20 (3H, m, aromatics), 7.05-6.99 (2H, m, 
aromatics), 6.96 (2H, d, J =8.8 Hz, aromatics), 5.42 (1H, d, J = 16.8 Hz, PhCH2), 5.35 (1H, d, 
J = 16.8 Hz, PhCH2), 4.35 (1H, d, J = 9.6 Hz, H-1’), 3.84 (1H, pseudo t, J = 10.8 Hz, 9.6 Hz, 
H-2’ or H-3’ or H-4’), 3.78 (3H, s, OMe), 3,77 (1H, dd, J = 12.4, 2.3 Hz, H-6’a), 3.61 (1H, 
dd, J = 12.4, 5.3 Hz, H-6’b), 3.41-3.29 (3H, m, H-2’ and/or H-3’ and/or H-4’, H-5’); 13C 
NMR (CD3OD) δ (ppm): 163.0 (4-MeOPh C-4), 157.2, 154.9 (triazole C-3, C-5), 136.9, 
131.6 (2), 130.1 (2), 129.1, 127.5 (2), 119.5, 115.5 (2) (aromatics), 82.4, 79.3, 74.2, 73.6, 71.1 
(C-1’ – C-5’), 62.6 (C-6’) 55.9 (OMe), 48.6 (PhCH2). Anal: Calcd for C22H25N3O6 (427.45): 
C, 61.82; H, 5.90; N, 9.83. Found: C, 61.87; H, 6.02; N, 9.75. 
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4.21. 4-Benzyl-3-(β-D-glucopyranosyl)-5-(4-nitrophenyl)-1,2,4-triazole (4j) 
From triazole 3j (0.23 g, 0.27 mmol) according to General procedure III. Reaction time: 6 
hours. The product precipitated from the reaction mixture and was used after filtration without 
further purification. Yield: 0.11 g (91 %), pale yellow needles. Mp: 153-155 °C; [α]D = −20 (c 
0.50, MeOH); 1H NMR (CD3OD) δ (ppm): 8.29 (2H, d, J = 8.6 Hz, aromatics), 7.75 (2H, d, J 
= 8.6 Hz, aromatics), 7.28 (3H, m, aromatics), 7.05 (2H, d, J = 6.3 Hz, aromatics), 5.54 (1H, 
d, J = 16.8 Hz, PhCH2), 5.48 (1H, d, J = 16.8 Hz, PhCH2), 4.48 (1H, d, J = 9.7 Hz, H-1’), 
3.98 (1H, pseudo t, J = 8.9, 8.9 Hz, H-2’ or H-3’ or H-4’), 3.82 (1H, dd, J = 11.9, < 1 Hz, H-
6’a), 3.65 (1H, dd, J = 12.0, 5.4 Hz, H-6’b), 3.50-3.43 (2 x 1H, m, H-2’ and/or H-3’ and/or H-
4’), 3.72 (1H, m, H-5’); 13C NMR (CD3OD) δ (ppm): 155.9, 155.5 (triazole C-3, C-5), 150.4, 
136.5, 133.9, 131.4 (2), 130.2 (2), 129.3, 127.7 (2), 125.0 (2) (aromatics), 82.6, 79.4, 74.2, 
73.7, 71.2 (C-1’ – C-5’), 62.7 (C-6’), 49.0 (PhCH2). Anal: Calcd for C21H22N4O7 (442.42): C, 
57.01; H, 5.01; N, 12.66. Found: C, 56.87; H, 5.11; N, 12.54. 
 
4.22. 4-Benzyl-5-(3,5-dimethylphenyl)-3-(β-D-glucopyranosyl)-1,2,4-triazole (4m) 
From triazole 3m (0.64 g, 0.76 mmol) according to General procedure III. Reaction time: 3 
hours. Purified by column chromatography (4:1 CHCl3-MeOH) to yield 0.20 g (62 %) of 
yellow syrup. Rf: 0.66 (7:3 CHCl3-MeOH); [α]D = −8 (c 0.69, MeOH); 1H NMR (CD3OD) δ 
(ppm): 7.25-6.95 (8H, m, aromatics), 5.36 (1H, d, J = 16.8 Hz, PhCH2), 5.29 (1H, d, J = 16.8 
Hz, PhCH2), 4.38 (1H, d, J = 9.7 Hz, H-1’), 3.96 (1H, pseudo t, J = 9.3, 8.9 Hz, H-2’ or H-3’ 
or H-4’), 3.76 (1H, dd, J = 12.2, 1.4 Hz, H-6’a), 3.60 (1H, dd, J = 12.2, 5.4 Hz, H-6’b), 3.48-
3.40 (2H, m, H-2’ and/or H-3’ and/or H-4’), 3.33-3.28 (1H, m, H-5’), 2.18 (6H, s, 2 x CH3); 
13C NMR (CD3OD) δ (ppm): 157.7, 155.2 (triazole C-3, C-5), 140.2 (2), 137.2, 133.4, 130.3 
(2), 129.4, 128.0 (2), 127.9 (2), 127.6 (aromatics), 82.7, 79.5, 74.4, 73.8, 71.3 (C-1’ – C-5’), 
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62.9 (C-6’), 49.1 (PhCH2), 21.6 (2 x CH3). Anal: Calcd for C23H27N3O5 (425.48): C, 64.93; H, 
6.40; N, 9.88. Found: C, 65.02; H, 6.47; N, 9.74. 
 
4.23. 4-Benzyl-3-(β-D-glucopyranosyl)-5-(3,4,5-trimethoxyphenyl)-1,2,4-triazole (4p) 
From triazole 3p (0.42 g, 0.46 mmol) according to General procedure III. Reaction time: 6 
hours. Purified by column chromatography (9:1 → 4:1CHCl3-MeOH) to yield 0.20 g (91 %) 
colourless syrup. Rf: 0.42 (4:1 CHCl3-MeOH); [α]D = −17 (c 0.53, MeOH); 1H NMR 
(CD3OD) δ (ppm): 7.38-7.28 (3H, m, aromatics), 7.12 (2H, d, J = 7.3 Hz, aromatics), 6.69 
(2H, s, aromatics), 5.50 (1H, d, J = 17.1 Hz, PhCH2), 5.42 (1H, d, J = 17.1 Hz, PhCH2), 4.45 
(1H, d, J = 9.6 Hz, H-1’), 4.00 (1H, pseudo t, J = 8.6, 9.6 Hz, H-2’ or H-3’ or H-4’), 3.80 (1H, 
dd, J = 12.0, < 1 Hz, H-6’a), 3.77 (4H, m, H-6’b, 1 x OMe), 3.63 (7H, m, H-6’b, 2 x OMe), 
3.50-3.43 (2 x 1H, m, H-2’ and/or H-3’ and/or H-4’), 3.63 (1H, m, H-5’); 13C NMR (CD3OD) 
δ (ppm): 157.2, 155.2 (triazole C-3, C-5), 154.9 (2), 141.0, 137.4, 130.2 (2), 129.1, 127.4 (2), 
122.8, 107.5 (2) (aromatics), 82.5, 79.3, 74.2, 73.6, 71.1 (C-1’ – C-5’), 62.8 (C-6’), 61.1 
(OMe), 56.6 (2 x OMe), 48.8 (PhCH2). Anal: Calcd for C24H29N3O8 (487.50): C, 59.13; H, 
6.00; N, 8.62. Found: C, 59.22; H, 6.09; N, 8.49. 
 
4.24. 4-Benzyl-3-(β-D-glucopyranosyl)-5-(2-naphthyl)-1,2,4-triazole (4q) 
From triazole 3q (0.50 g, 0.58 mmol) according to General procedure III. Reaction time: 3 
hours. Purified by column chromatography (9:1 CHCl3-MeOH) to yield 0.22 g (85 %) white 
crystals. Mp: 243-245 °C; [α]D = −19 (c 0.51, MeOH); 1H NMR (DMSO-d6) δ (ppm): 8.03-
7.02 (12H, m, aromatics), 5.48 (1H, d, J = 16.9 Hz, PhCH2), 5.42 (1H, d, J = 16.9 Hz, 
PhCH2), 4.35 (1H, d, J = 9.3 Hz, H-1’), 3.86 (1H, pseudo t, J = 9.3, 9.3 Hz, H-2’ or H-3’ or 
H-4’), 3.62 (1H, dd, J = 11.9, < 1 Hz, H-6’a), 3.42 (1H, dd, J = 11.9, 5.3 Hz, H-6’b), 3.31-
3.17 (3 x 1H, m, H-2’ and/or H-3’ and/or H-4’, H-5’); 13C NMR (DMSO-d6) δ (ppm): 154.3, 
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153.3 (triazole C-3, C-5), 136.1-124.6 (aromatics), 81.2, 78.0, 72.3, 71.4, 69.8 (C-1’ – C-5’), 
61.0 (C-6’), 46.8 (PhCH2). Anal: Calcd for C25H25N3O5 (447.48): C, 67.10; H, 5.63; N, 9.39. 
Found: C, 67.02; H, 5.74; N, 9.27. 
 
4.25. 5-(4-Carboxyphenyl)-3-(2’,3’,4’,6’-tetra-O-benzoyl-β-D-glucopyranosyl)-1,2,4-
triazole (5l) 
Triazole 3s (0.56 g, 0.59 mmol) was dissolved in anhydrous EtOAc (35 mL), 10% Pd(C) (55 
mg) was added and H2 was bubbled through the reaction mixture at 50°C. After 
disappearance of the starting material (6 hours, monitored by TLC, 1:1 EtOAc-hexane) the 
reaction was filtered through a pad of celite, the solvent was evaporated, and the residue was 
purified by column chromatography (EtOAc) to yield 0.34 g (75 %) colourless syrup. Rf: 0.58 
(1:3 AcOH-toluene); [α]D = −33 (c 0.48, MeOH); 1H NMR (CD3OD) δ (ppm): 8.02-7.12 
(24H, m, aromatics), 6.24 (1H, pseudo t, J = 9.5, 9.5 Hz, H-3’), 6.08 (1H, pseudo t, J = 9.6, 
9.5 Hz, H-2’), 5.95 (1H, pseudo t, J = 9.5, 9.5 Hz, H-4’), 5.38 (1H, d, J = 9.9 Hz, H-1’), 4.66-
4.58 (3H, m, H-6’a, H-6’b, H-5’); 13C NMR (CD3OD) δ (ppm): 169.2 (COOH), 167.6, 167.2, 
166.7, 166.4 (CO), 134.7-127.4 (aromatics), 77.7 (C-5’), 75.7 (C-3’), 74.8 (C-1’), 73.1 (C-2’), 
71.1 (C-4’), 64.6 (C-6’). Anal: Calcd for C43H33N3O11 (767.74): C, 67.27; H, 4.33; N, 5.47. 
Found: C, 67.14; H, 4.47; N, 5.39.  
 
4.26. 3-(β-D-Glucopyranosyl)-5-methyl-1,2,4-triazole[54] (6a)  
From triazole 5a [62] (0.25 g, 0.38 mmol) according to General procedure III. Reaction time: 
3 days. Purified by column chromatography (7:3 CHCl3-MeOH) to yield 0.07 g (73 %) 
colourless syrup. Rf: 0.55 (1:1 CHCl3-MeOH); [α]D = +21 (c 0.36, MeOH); 1H NMR (D2O) δ 
(ppm): 4.36 (1H, d, J = 9.2 Hz, H-1’), 3.82 (1H, dd, J = 11.9, < 1 Hz, H-6’a), 3.68-3.63 (2H, 
m, H-2’ or H-3’ or H-4’, H-6’b), 3.56-3.43 (3H, m, H-2’ and/or H-3’ and/or H-4’, H-5’), 2.36 
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(3H, s, CH3); 13C NMR (D2O) δ (ppm): 159.6, 156.2 (triazole C-3, C-5), 80.8, 77.7, 75.3, 
73.1, 70.1 (C-1’ – C-5’), 61.5 (C-6’), 11.4 (CH3). Anal: Calcd for C9H15N3O5 (245.23): C, 
44.08; H, 6.17; N, 17.13. Found: C, 44.19; H, 6.23; N, 17.01. 
 
4.27. 5-(tert-Butyl)-3-(β-D-glucopyranosyl)-1,2,4-triazole (6b)  
From triazole 5b [62] (0.25 g, 0.36 mmol) according to General procedure III. Reaction time: 
2 days. (The mixture was neutralised with acetic acid.) Purified by column chromatography 
(4:1 CHCl3-MeOH) to yield 0.10 g (98 %) colourless syrup. Rf: 0.51 (7:3 CHCl3-MeOH); 
[α]D = –6 (c 0.25, MeOH); 1H NMR (CD3OD) δ (ppm): 4.33 (1H, d, J = 8.6 Hz, H-1’), 3.82 
(1H, dd, J = 11.9, 2.5 Hz, H-6’a), 3.69-3.64 (2H, m, H-2’ or H-3’ or H-4’, H-6’b), 3.50-3.40 
(3H, m, H-2’ and/or H-3’ and/or H-4’, H-5’), 1.34 (9H, s, C(CH3)3); 13C NMR (CD3OD) δ 
(ppm): 166.6, 162.1 (triazole C-3, C-5), 82.2, 79.3, 76.9, 74.2, 71.2 (C-1’ – C-5’), 62.8 (C-6’), 
33.3 (C(CH3)3) 29.6 (C(CH3)3). Anal: Calcd for C12H21N3O5 (287.31): C, 50.16; H, 7.37; N, 
14.63. Found: C, 50.09; H, 7.52; N, 14.57. 
 
4.28. 3-(β-D-Glucopyranosyl)-5-hydroxymethyl-1,2,4-triazole[54] (6c)  
From triazole 5t [62] (0.18 g, 0.25 mmol) according to General procedure III. Reaction time: 
5 days. (The mixture was neutralised with acetic acid.) Purified by column chromatography 
(3:2 CHCl3-MeOH) to yield 0.06 g (93 %) colourless syrup. Rf: 0.38 (1:1 CHCl3-MeOH); 
[α]D = –3 (c 0.42, MeOH); 1H NMR (CD3OD) δ (ppm): 4.67 (2H, s, CH2), 4.35 (1H, d, J = 
9.2 Hz, H-1’), 3.83 (1H, dd, J = 12.3, < 1 Hz, H-6’a), 3.68-3.59 (2H, m, H-2’ or H-3’ or H-4’, 
H-6’b), 3.49-3.40 (3H, m, H-2’ and/or H-3’ and/or H-4’, H-5’); 13C NMR (CD3OD) δ (ppm): 
160.5, 160.4 (triazole C-3, C-5), 82.2, 79.2, 76.3, 74.4, 71.2 (C-1’ – C-5’), 62.8 (C-6’), 57.4 
(CH2). Anal: Calcd for C9H15N3O6 (261.23): C, 41.38; H, 5.79; N, 16.09. Found: C, 41.31; H, 
5.91; N, 16.23. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
24 
 
 
4.29. 3-(β-D-Glucopyranosyl)-5-phenyl-1,2,4-triazole[54] (6d) 
A) From triazole 4d (0.20 g, 0.50 mmol) according to General procedure IV. Reaction time: 4 
hours. Purified by column chromatography (4:1 CHCl3-MeOH) to yield 0.13 g (85 %) 
colourless syrup.  
B) From triazole 5d [62] (0.25 g, 0.35 mmol) according to General procedure III. Reaction 
time: 3 days. Purified by column chromatography (4:1 CHCl3-MeOH) to yield 0.07 g (62 %) 
colourless syrup. Rf: 0.48 (7:3 CHCl3-MeOH); [α]D = +31 (c 0.20, H2O); 1H NMR (D2O) δ 
(ppm): 7.66 (2H, d, J = 7.9 Hz, aromatics), 7.38-7.36 (3H, m, aromatics), 4.45 (1H, d, J = 9.2 
Hz, H-1’), 3.87 (1H, dd, J = 11.9, < 1 Hz, H-6’a), 3.77-3.69 (2H, m, H-2’ or H-3’ or H-4’, H-
6’b), 3.64-3.54 (3H, m, H-2’ and/or H-3’ and/or H-4’, H-5’); 13C NMR (D2O) δ (ppm): 159.1, 
157.8 (triazole C-3, C-5), 130.9, 129.3 (2), 126.9, 126.5 (2) (aromatics), 80.2, 77.2, 74.7, 72.8, 
69.5 (C-1’ – C-5’), 61.0 (C-6’). Anal: Calcd for C14H17N3O5 (307.30): C, 54.72; H, 5.58; N, 
13.67. Found: C, 54.85; H, 5.45; N, 13.54.  
 
4.30. 3-(β-D-Glucopyranosyl)-5-(4-methylphenyl)-1,2,4-triazole (6e) 
From triazole 4e (0.20 g, 0.49 mmol) according to General procedure IV. Reaction time: 3 
hours. Purified by column chromatography (4:1 CHCl3-MeOH) to yield 0.14 g (90 %) white 
foam. Rf: 0.51 (7:3 CHCl3-MeOH); [α]D = +6 (c 0.45, MeOH); 1H NMR (D2O) δ (ppm): 7.31 
(2H, d, J = 7.9 Hz, aromatics), 6.93 (2H, d, J = 7.9 Hz, aromatics), 4.36 (1H, d, J = 9.5 Hz, H-
1’), 3.83 (1H, dd, J = 11.9, < 1 Hz, H-6’a), 3.72 (1H, dd, J = 11.9, 3.1 Hz, H-6’b), 3.66 (1H, 
pseudo t, J = 9.2, 8.9 Hz, H-2’ or H-3’ or H-4’), 3.59-3.50 (3H, m, H-2’ and/or H-3’ and/or 
H-4’, H-5’), 2.06 (3H, s, CH3); 13C NMR (D2O) δ (ppm): 159.5, 157.5 (triazole C-3, C-5), 
141.9, 130.0 (2), 126.6 (2), 123.8 (aromatics), 80.5, 77.6, 75.2, 73.3, 69.9 (C-1’ – C-5’), 61.4 
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(C-6’), 21.1 (CH3). Anal: Calcd for C15H19N3O5 (321.33): C, 56.07; H, 5.96; N, 13.08. Found: 
C, 55.98; H, 5.85; N, 12.96. 
 
4.31. 5-(4-tert-Butylphenyl)-3-(β-D-glucopyranosyl)-1,2,4-triazole[54] (6f)  
From triazole 4f (0.20 g, 0.44 mmol) according to General procedure IV. Reaction time: 3 
hours. Purified by column chromatography (4:1 CHCl3-MeOH) to yield 0.13 g (79 %) 
colourless syrup. Rf: 0.22 (4:1 CHCl3-MeOH); [α]D = +8 (c 0.55, DMSO); 1H NMR (CD3OD) 
δ (ppm): 7.90 (2H, d, J = 8.0, aromatics), 7.51 (2H, d, J = 8.0, aromatics), 4.48 (1H, d, J = 9.5 
Hz, H-1’), 3.90 (1H, dd, J = 11.5, < 1 Hz, H-6’a), 3.77-3.73 (2H, m, H-2’ or H-3’ or H-4’, H-
6’b), 3.59-3.51 (3H, m, H-2’ and/or H-3’ and/or H-4’, H-5’), 1.33 (9H, s, C(CH3)3); 13C NMR 
(CD3OD) δ (ppm): 161.6, 158.1 (triazole C-3, C-5), 154.7, 127.4 (2), 126.9 (2) (aromatics), 
82.0, 79.1, 76.3, 74.3, 71.1 (C-1’ – C-5’), 62.6 (C-6’), 35.7 (C(CH3)3), 31.6 (C(CH3)3). Anal: 
Calcd for C18H25N3O5 (363.41): C, 59.49; H, 6.93; N, 11.56. Found: C, 59.60; H, 6.84; N, 
11.47. MS-ESI (m/z): 386.169 [M+Na]+ 
 
 
4.32. 3-(β-D-Glucopyranosyl)-5-(4-trifluoromethylphenyl)-1,2,4-triazole (6g) 
From triazole 4g (85 mg, 0.18 mmol) according to General procedure IV. Reaction time: 1.5 
hours. Purified by column chromatography (9:1 CHCl3-MeOH) to yield 52 mg (77 %) white 
amorphous solid. Rf: 0.20 (4:1 CHCl3-MeOH); [α]D = +13 (c 0.52, MeOH); 1H NMR 
(CD3OD) δ (ppm): 8.09 (2H, br s, aromatics), 7.66 (2H, br s, aromatics), 4.40 (1H, d, J = 7.2 
Hz, H-1’), 3.80 (1H, dd, J = 10.7, < 1 Hz, H-6’a), 3.66-3.20 (5H, m, H-2’, H-3’, H-4’, H-5’, 
H-6’b); 13C NMR (CD3OD) δ (ppm): 160.2, 159.1 (triazole C-3, C-5), 134.9, 132.3 (q, 2J(C, F) 
= 34.6 Hz, C-CF3), 127.9 (2), 126.8 (2) (aromatics), 125.6 (q, 1J(C, F) = 271.3 Hz, CF3), 82.3, 
79.2, 75.9, 74.6, 71.2 (C-1’ – C-5’), 62.7 (C-6’). Anal: Calcd for C15H16F3N3O5 (375.30): C, 
48.00; H, 4.30; N, 11.20. Found: C, 48.12; H, 4.35; N, 11.07. 
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4.33. 3-(β-D-Glucopyranosyl)-5-(4-hydroxyphenyl)-1,2,4-triazole (6h)  
From triazole 5u [62] (0.57 g, 0.73 mmol) according to General procedure III. Purified by 
column chromatography (4:1 CHCl3-MeOH) to yield 0.16 g (67%) white solid. Mp: 172-174 
°C; [α]D = +14 (c 0.35, DMSO); 1H NMR (CD3OD) δ (ppm): 7.69 (2H, d, J = 8.2 Hz, 
aromatics), 6.79 (2H, d, J = 8.5 Hz, aromatics), 4.38 (1H, d, J = 9.6 Hz, H-1’) 3.82 (1H, d, J = 
11.0, < 1 Hz, H-6’a), 3.68-3.64 (2H, m, H-2’ or H-3’ or H-4’, H-6’b), 3.53-3.41 (3H, m, H-2’ 
and/or H-3’ and/or H-4’, H-5’); 13C NMR (CD3OD) δ (ppm): 162.1, 160.6, 157.6 (triazole C-
3, C-5, 4-HOPh C-4), 129.2 (2), 126.9, 116.8 (2) (aromatics), 82.0, 79.2, 76.5, 74.4, 71.2 (C-
1’ – C-5’), 62.7 (C-6’). Anal: Calcd for C14H17N3O6 (323.30): C, 52.01; H, 5.30; N, 13.00. 
Found: C, 51.93; H, 5.41; N, 13.12. 
 
4.34. 3-(β-D-Glucopyranosyl)-5-(4-methoxyphenyl)-1,2,4-triazole (6i) 
From triazole 4i (0.24 g, 0.55 mmol) according to General procedure IV. Purified by column 
chromatography (7:3 CHCl3-MeOH) to yield 0.18 g (95 %) colourless syrup. Rf: 0.52 (7:3 
CHCl3-MeOH); [α]D = +12 (c 0.41, MeOH); 1H NMR (CD3OD) δ (ppm): 7.82 (2H, d, J = 8.3 
Hz, aromatics), 6.92 (2H, d, J = 8.3 Hz, aromatics), 4.46 (1H, d, J = 9.5 Hz, H-1’), 3.86 (1H, 
dd, J = 12.1, < 1 Hz, H-6’), 3.75 (5H, m, H-2’ and/or H-3’ and/or H-4’, H-6’b, OMe), 3.60-
3.50 (3H, m, H-2’ and/or H-3’ and/or H-4’, H-5’); 13C NMR (CD3OD) δ (ppm): 162.6 (4-
MeOPh C-4), 160.1, 159.1 (triazole C-3, C-5), 129.0 (2), 121.5, 115.3 (2) (aromatics), 82.0, 
79.1, 76.3, 74.3, 71.1 (C-1’ – C-5’), 62.7 (C-6’), 55.9 (OMe). Anal: Calcd for C15H19N3O6 
(337.33): C, 53.41; H, 5.68; N, 12.46. Found: C, 53.55; H, 5.63; N, 12.56.  
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4.35. 3-(β-D-Glucopyranosyl)-5-(4-nitrophenyl)-1,2,4-triazole (6j)  
From triazole 5j [62] (0.65 g, 0.85 mmol) according to General procedure III. Reaction time: 
1 day. Purified by column chromatography (4:1 CHCl3-MeOH) to yield 0.22 g (75 %) pale 
yellow solid. Mp: 166-169 °C; [α]D = +20 (c 1.3, DMSO); 1H NMR (DMSO-d6) δ (ppm): 
8.34 (2H, d, J = 8.2 Hz, aromatics), 8.26 (2H, d, J = 7.8 Hz, aromatics), 5.15, 5.10, 4.57 (4H, 
3 br s, OH), 4.34 (1H, d, J = 9.7 Hz, H-1’), 3.71 (1H, dd, J = 11.7, 5.4 Hz, H-6’a), 3.63 (1H, 
pseudo t, J = 9.2, 9.0 Hz, H-2’ or H-3’ or H-4’), 3.46-3.28 (3H, m, H-2’ and/or H-3’and/or H-
4’, H-5’, H-6’b), 3.18 (1H, pseudo t, J = 9.0, 8.9 Hz, H-2’ or H-3’ or H-4’); 13C NMR 
(DMSO-d6) δ (ppm): 158.2, 157.0 (triazole C-3, C-5), 147.5, 136.7, 126.8 (2), 124.2 (2) 
(aromatics), 81.6, 77.9, 74.0, 72.5, 70.0 (C-1’ – C-5’), 61.2 (C-6’). Anal: Calcd for 
C14H16N4O7 (352.30): C, 47.73; H, 4.58; N, 15.90. Found: C, 47.81; H, 4.62; N, 15.78. MS-
ESI (m/z): 375.093 [M+Na]+. 
 
4.36. 5-(4-Aminophenyl)-3-(β-D-glucopyranosyl)-1,2,4-triazole (6k)  
Triazole 6j (0.10 g, 0.28 mmol) was dissolved in dry MeOH (3 mL), and 0.01g Pd-C (10%) 
was added. The reaction mixture was stirred at rt under hydrogen atmosphere for one hour. 
After completion of the transformation monitored by TLC (1:1 CHCl3-MeOH) Pd-C was 
filtrated through a pad of celite, the solvent was evaporated in vacuo and the residue was 
purified by column chromatography (4:1 CHCl3-MeOH) to yield 0.09 g (94 %) amorphous 
yellow product. Rf: 0.59 (1:1 CHCl3-MeOH); [α]D = +9 (c 1.46, DMSO); 1H NMR (DMSO-
d6) δ (ppm): 7.64 (2H, d, J = 8.0 Hz, aromatics), 6.60 (2H, d, J = 8.0 Hz, aromatics), 5.51 
(2H, br s, NH2), 4.98, 4.79, 4.53 (4H, 3 br s, OH), 4.13 (1H, d, J = 9.2 Hz, H-1’), 3.70-3.64 
(2H, m, H-2’or H-3’ or H-4’, H-6’a), 3.42-3.16 (4H, m, H-2’ and/or H-3’ and/or H-4’, H-5’, 
H-6’b); 13C NMR (DMSO-d6) δ (ppm): 161.3, 155.0 (triazole C-3, C-5), 150.3, 127.1 (2), 
114.7, 113.6 (2) (aromatics), 81.4, 78.3, 75.7, 72.4, 70.2 (C-1’ – C-5’), 61.3 (C-6’). Anal: 
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Calcd for C14H18N4O5 (322.32): C, 52.17; H, 5.63; N, 17.38. Found: C, 52.21; H, 5.55; N, 
17.26. MS-ESI (m/z): 345.118 [M+Na]+. 
 
4.37. 5-(4-Carboxyphenyl)-3-(β-D-glucopyranosyl)-1,2,4-triazole (6l) 
From triazole 5l (0.24 g, 0.32 mmol) according to General procedure III. Reaction time: 5 
days. Purified by column chromatography (1:1 CHCl3-MeOH) to yield 0.10 g (86 %) 
yellowish syrup. Rf: 0.55 (1:1:1 toluene-AcOH-MeOH); [α]D = +6 (c 0.54, MeOH); 1H NMR 
(DMSO-d6) δ (ppm): 8.10-8.04 (4H, m, aromatics), 4.33 (1H, d, J = 9.7 Hz, H-1’), 3.74-3.65 
(2H, m, H-2’ and/or H-3’ and/or H-4’, H-6’a), 3.47 (1H, ddd, J = 8.9, 5.3, < 1 Hz, H-5’), 
3.37-3.25 (2H, m, H-2’ and/or H-3’ and/or H-4’, H-6’b), 3.20 (1H, pseudo t, J = 9.0, 8.9 Hz, 
H-2’ or H-3’ or H-4’); 13C NMR (DMSO-d6) δ (ppm): 168.7 (COOH), 158.4, 157.8 (triazole 
C-3, C-5), 134.1, 133.1, 129.9 (2), 125.7 (2) (aromatics), 81.6, 78.1, 74.5, 72.6, 70.2 (C-1’ – 
C-5’), 61.3 (C-6’). Anal: Calcd for C15H17N3O7 (351.31): C, 51.28; H, 4.88; N, 11.96. Found: 
C, 51.15; H, 4.96; N, 11.89. 
 
4.38. 5-(3,5-Dimethylphenyl)-3-(β-D-glucopyranosyl)-1,2,4-triazole (6m) 
From triazole 4m (0.14 g, 0.34 mmol) according to General procedure IV. Reaction time: 3 
hours. Purified by column chromatography (4:1 CHCl3-MeOH) to yield 0.11 g (98 %) 
colourless syrup. Rf: 0.54 (3:1 CHCl3-MeOH); [α]D = +12 (c 0.57, MeOH); 1H NMR 
(CD3OD) δ (ppm): 7.48 (2H, s, aromatics), 6.99 (1H, s, aromatic), 4.43 (1H, d, J = 9.6 Hz, H-
1’), 3.85 (1H, dd, J = 12.0, 1.3 Hz, H-6’a), 3.73-3.68 (2H, m, H-2’ or H-3’ or H-4’, H-6’b,), 
3.56-3.40 (3H, m, H-2’and/or H-3’and/or H-4’, H-5’), 2.25 (6H, s, 2 x CH3); 13C NMR 
(CD3OD) δ (ppm): 162.2, 157.6 (triazole C-3, C-5), 139.7 (2), 132.7, 128.0, 125.2 (2) 
(aromatics), 82.0, 79.1, 76.2, 74.3, 71.1 (C-1’ – C-5’), 62.7 (C-6’), 21.3 (2 x CH3). Anal: 
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Calcd for C16H21N3O5 (335.36): C, 57.30; H, 6.31; N, 12.53. Found: C, 57.41; H, 6.24; N, 
12.41. 
 
4.39. 5-(3,5-Dinitrophenyl)-3-(β-D-glucopyranosyl)-1,2,4-triazole (6n)  
From triazole 5n [62] (0.52 g, 0.63 mmol) according to General procedure III. Reaction time: 
3 day. Purified by column chromatography (7:3 CHCl3-MeOH) to yield 0.18 g (72%) white 
solid. Mp: 203-205 ºC; [α]D = –21 (c 0.11, DMSO); 1H NMR (DMSO-d6-D2O) δ (ppm): 9.02 
(2H, s, aromatics), 8.83 (1H, s, aromatic), 4.37 (1H, d, J = 9.8 Hz, H-1’), 3.69 (1H, dd, J = 
11.9, < 1 Hz, H-6’a), 3.58 (1H, pseudo t, J = 9.1, 9.1 Hz, H-2’ or H-3’ or H-4’), 3.47 (1H, dd, 
J = 11.9, 5.6 Hz, H-6’b), 3.35-3.30 (2H, m, H-2’ or H-3’ or H-4’, H-5’), 3.22 (1H, pseudo t, J 
= 9.1, 9.1 Hz, H-2’ or H-3’ or H-4’); 13C NMR (DMSO-d6) δ (ppm): 162.2, 157.3 (triazole C-
3, C-5), 148.5 (2), 137.7, 124.1 (2), 115.5 (aromatics), 80.8, 77.9, 75.8, 73.2, 70.5 (C-1’ – C-
5’), 61.3 (C-6’). Anal: Calcd for C14H15N5O9 (397.30): C, 42.32; H, 3.81; N, 17.63. Found: C, 
42.39; H, 3.93; N, 17.56. 
 
4.40. 5-(3,5-Diaminophenyl)-3-(β-D-glucopyranosyl)-1,2,4-triazole (6o)  
Triazole 6n (0.07 g, 0.18 mmol) was dissolved in dry MeOH (10 mL), and 0.015g Pd-C 
(10%) was added. The reaction mixture was stirred at rt under hydrogen atmosphere for one 
hour. After completion of the transformation monitored by TLC (1:1 CHCl3-MeOH) Pd-C 
was filtrated through a pad of celite, the solvent was evaporated in vacuo and the residue was 
purified by column chromatography (1:1 CHCl3-MeOH) to yield 0.04 g (72 %) amorphous 
brownish product. Rf: 0.33 (1:1 CHCl3-MeOH); 1H NMR (DMSO-d6-D2O) δ (ppm): 6.49 
(2H, d, J = 2.0 Hz, aromatics), 5.84 (1H, t, J = 2.0, aromatic), 4.16 (1H, d, J = 9.9 Hz, H-1’), 
3.65 (1H, dd, J = 12.6, < 1 Hz, H-6’a), 3.57 (1H, pseudo t, J = 9.9, 9.2 Hz, H-2’ or H-3’ or H-
4’), 3.42 (1H, dd, J = 12.6, 4.9 Hz, H-6’b), 3.32-3.17 (3H, m, H-2’ and/or H-3’ and/or H-4’, 
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H-5’); 13C NMR (DMSO-d6) δ (ppm): 159.7, 158.8 (triazole C-3, C-5), 149.6 (2), 130.6, 
102.3 (2), 102.1 (aromatics), 81.2, 78.2, 75.4, 73.1, 70.3 (C-1’ – C-5’), 61.5 (C-6’). Anal: 
Calcd for C14H19N5O5 (337.33): C, 49.85; H, 5.68; N, 20.76. Found: C, 49.99; H, 5.75; N, 
20.64. 
 
4.41. 3-(β-D-Glucopyranosyl)-5-(3,4,5-trimethoxyphenyl)-1,2,4-triazole (6p) 
From triazole 4p (0.18 g, 0.37 mmol) according to General procedure IV. Reaction time: 3 
hours. Purified by column chromatography (9:1 CHCl3-MeOH) to yield 0.14 g (92 %) 
colourless syrup. Rf: 0.37 (4:1 CHCl3-MeOH); [α]D = +5 (c 0.44, MeOH); 1H NMR (D2O) δ 
(ppm): 6.64 (2H, s, aromatics), 4.57 (1H, d, J = 9.3 Hz, H-1’), 4.05 (1H, dd, J = 11.9, < 1 Hz, 
H-6’a), 3.92 (1H, dd, J = 11.9, < 1 Hz, H-6’b), 3.88-3.72 (4H, m, H-2’, H-3’, H-4’, H-5’), 
3.65-3.64 (9H, m, 3 x OMe); 13C NMR (D2O) δ (ppm): 159.8, 157.4 (triazole C-3, C-5), 152.6 
(2), 138.3, 122.7, 103.2 (2) (aromatics), 80.5, 77.5, 75.0, 73.4, 70.0 (C-1’ – C-5’), 61.5 (C-6’), 
61.2 (OMe), 56.1 (2 x OMe). Anal: Calcd for C17H23N3O8 (397.38): C, 51.38; H, 5.83; N, 
10.57. Found: C, 51.25; H, 5.94; N, 10.64. 
 
4.42. 3-(β-D-Glucopyranosyl)-5-(2-naphthyl)-1,2,4-triazole[54] (6q) 
A) From triazole 4q (0.10 g, 0.23 mmol) according to General procedure IV. Reaction time: 3 
hours. Purified by column chromatography (4:1 CHCl3-MeOH) to yield 0.07 g (90 %) 
colourless syrup.  
B) From triazole 5q [62] (0.27 g, 0.35 mmol) according to General procedure III. Reaction 
time: 3 days. Purified by column chromatography (9:1 CHCl3-MeOH) to yield 0.10 g (81 %) 
colourless syrup. Compound characterization data were identical with those reported in our 
preliminary communication [54].  
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4.43. 3-(β-D-Glucopyranosyl)-5-(2-pyridyl)-1,2,4-triazole (6r) 
From triazole 5r [62] (0.31 g, 0.43 mmol) according to General procedure III. Reaction time: 
3.5 hours. Purified by column chromatography (7:3 CHCl3-MeOH) to yield 0.05 g (40 %) 
colourless syrup. Rf: 0.36 (1:1 CHCl3-MeOH); [α]D = +30 (c 0.22, H2O); 1H NMR (D2O) δ 
(ppm): 8.49 (1H, d, J = 4.0 Hz, Py), 7.85-7.78 (2H, m, Py), 7.41-7.38 (1H, m, Py), 4.57 (1H, 
d, J = 9.2 Hz, H-1’), 3.94 (1H, dd, J = 11.9, < 1 Hz, H-6’a), 3.83-3.76 (2H, m, H-2’ or H-3’ or 
H-4’, H-6’b), 3.70-3.57 (3H, m, H-2’ and/or H-3’ and/or H-4’, H-5’); 13C NMR (D2O) δ 
(ppm): 158.5, 156.8 (triazole C-3, C-5), 149.4, 145.3, 138.3, 125.5, 122.0 (Py), 80.0, 76.8, 
74.3, 72.5, 69.3 (C-1’ – C-5’), 60.7 (C-6’). Anal: Calcd for C13H16N4O5 (308.29): C, 50.65; H, 
5.23; N, 18.17. Found: C, 50.77; H, 5.10; N, 18.29. MS-ESI (m/z): 331.100 [M+Na]+, 639.217 
[2M+Na]+, 309.118 [M+H]+. 
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Chart 1. Glycogen phosphorylase inhibitors (GPIs, Ki [µM] against rabbit muscle GPb, I-VIII); synthetic 
targets of this study (IX); outline of binding of glucose analogues at the active site of GP highlighting 
important H-bonds to His377 and interactions in the so-called β-channel for N-acyl-β-D-
glucopyranosylamine type inhibitors (X) and 2-β-D-glucopyranosyl benzimidazole (XI) as observed by X-ray 
crystallography. 
R =  CH3 
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HO
HO
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∗A Ki value of 2.4 µM was measured by N. G. Oikonomakos et al. (unpublished results in ref. [51]) 
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Scheme 1. Retrosynthetic analysis of the target compounds IX based on 1,3-dipolar cycloadditions 
(Glc = O-protected β-D-glucopyranosyl residue, PG = protecting group). 
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Table 1. Synthesis of 3-(β-D-glucopyranosyl)-5-substituted-1,2,4-triazoles 
OBzO
BzO
BzO
BzO
N
N
NHN OBzO
BzO
BzO
BzO
N
NN
R
Bn
OHO
HO
OH
HO
N
NN
R
Bn
OHO
HO
OH
HO
N
NHN
R
OBzO
BzO
BzO
BzO
N
NHN
RR NH
O
Bn + SOCl2
1 3 4
2 5 6
R N
Cl
Bn
solvent
reflux
MeONa (cat.)
     MeOH
MeONa (cat.)
     MeOH
rt
rt
H2/Pd(C) H2/Pd(C)
 
  Yield (%) 
 
R 3 (solvent) 4 5 6 
a CH3 - - see ref. [62] 73 (from 5a) 
b C(CH3)3 - - see ref. [62] 98 (from 5b) 
c CH2OH - - - 93 (from 5t) 
d C6H5 69 (toluene) 73  see ref. [62] 85 (from 4d) 62 (from 5d) 
e C6H4-4-CH3 49 (m-xylene) 94  - 90 (from 4e) 
f C6H4-4-C(CH3)3 61 (m-xylene) 98  - 79 (from 4f) 
g C6H4-4-CF3 88 (toluene) 61  - 77 (from 4g) 
h C6H4-4-OH - - - 67 (from 5u) 
i C6H4-4-OCH3 62 (m-xylene) 68  - 95 (from 4i) 
j C6H4-4-NO2 38 (toluene) 91  see ref. [62] 75 (from 5j) 
k C6H4-4-NH2 - - - 94 (from 6j) 
l C6H4-4-COOH - - 75 (from 3s) 86 (from 5l) 
m C6H3-3,5-(CH3)2 66 (m-xylene) 62  - 98 (from 4m) 
n C6H3-3,5-(NO2)2 - - see ref. [62] 72 (from 5n) 
o C6H3-3,5-(NH2)2 - - - 72 (from 6n) 
p C6H2-3,4,5-(OCH3)3 65 (m-xylene) 91  - 92 (from 4p) 
q C10H7 (2-naphthyl) 52 (toluene) 85  see ref. [62] 90 (from 4q) 81 (from 5q) 
r C5H4N (2-pyridyl) - - see ref. [62] 40 (from 5r) 
s C6H4-4-COOBn 69 (m-xylene) - - - 
t CH2OCOCH3 - - see ref. [62] - 
u C6H4-4-OCOCH3 - - see ref. [62] - 
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Table 2. Inhibition of rabbit muscle glycogen phosphorylase b by 3-(β-D-glucopyranosyl)-5-
substituted-1,2,4-triazoles (6) 
 
O
OH
HO
HO
OH
N
NHN
R
 
6 
 R Ki [µM]  R Ki [µM] 
a -CH3 499 j 
NO2
 
33.5 
b -C(CH3)3 no inh. at 625 µM k NH2
 
0.67 
c -CH2OH 105 l 
COOH
 
no inh. 
at 625 µM 
d 
 
7 m 
CH3
CH3
 
39.7 
e 
CH3
  
1.7 n 
NO2
NO2
 
no inh. 
at 625 µM 
f 
C(CH3)3
 
778 o 
NH2
NH2
 
14 
g 
CF3
 
111 p 
OCH3
OCH3
OCH3
 
518* 
h 
OH
 
2.9 q 
 
0.41 
i 
OCH3
 
1.9 r 
N
 
707 
*Calculated from the IC50 value by using a web-based tool [64]. 
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Legends: 
 
Chart 1. Glycogen phosphorylase inhibitors (GPIs, Ki [µM] against rabbit muscle GPb, I-
VIII); synthetic targets of this study (IX); outline of binding of glucose analogues at the 
active site of GP highlighting important H-bonds to His377 and interactions in the so-called 
β-channel for N-acyl-β-D-glucopyranosylamine type inhibitors (X) and 2-β-D-glucopyranosyl 
benzimidazole (XI) as observed by X-ray crystallography. 
 
Scheme 1. Retrosynthetic analysis of the target compounds IX based on 1,3-dipolar 
cycloadditions (Glc = O-protected β-D-glucopyranosyl residue, PG = protecting group). 
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Highlights 
 
• New synthesis of 3-(β-D-glucopyranosyl)-5-substituted-1,2,4-triazoles. 
• Carboximidoylation of O-protected 5-(β-D-glucopyranosyl)tetrazole. 
• New nanomolar inhibitors of glycogen phosphorylase. 
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SUPPORTING INFORMATION  
 
 
New synthesis of 3-(β-D-glucopyranosyl)-5-substituted-1,2,4-triazoles, 
nanomolar inhibitors of glycogen phosphorylase 
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1H and 13C NMR spectra for selected compounds.  
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1H and 13C NMR spectra of compound 3e in CDCl3. 
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1H and 13C NMR spectra of compound 4e in CD3OD. 
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1H and 13C NMR spectra of compound 6e in D2O. 
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 1H and 13C NMR spectra of compound 3p in CDCl3. 
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 1H and 13C NMR spectra of compound 4p in CD3OD. 
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 1H and 13C NMR spectra of compound 6p in D2O. 
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 1H and 13C NMR spectra of compound 3q in CDCl3. 
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 1H and 13C NMR spectra of compound 4q in DMSO-d6. 
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 1H and 13C NMR spectra of compound 6q in CD3OD and DMSO-d6, respectively. 
